GT Biopharma, Inc. (GTBP)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 80K 160K 240K Q3 '10: 0 Q4 '10: 11K Q1 '11: 20K Q2 '11: 1K Q3 '11: 2K Q4 '11: 3K Q1 '12: 1K Q2 '12: 1K Q3 '12: 120K Q4 '12: 219K Q1 '13: 88K Q2 '13: 56K Q3 '13: 183K Q4 '13: 41K Q1 '14: 0 Q2 '14: 25K Q3 '14: 3K Q4 '14: 33K Q1 '15: 7K Q2 '15: 20K Q3 '15: 0 Q4 '15: 0 Q1 '16: 0 Q2 '16: 0 Q3 '16: 0 Q4 '16: 0 Q1 '17: 0 Q2 '17: 0 Q3 '17: 0 Q4 '17: 0 Q1 '18: 0 Q2 '18: 0 Q1 '19: 0 Q1 '20: 0 Q2 '20: 0 Q3 '20: 0 Q4 '20: 0 Q1 '21: 0 Q2 '21: 0 Q3 '21: 0 Q3 '11 Q4 '12 Q1 '14 Q2 '15 Q3 '16 Q4 '17 Q2 '20 Q3 '21

Gross Profit Quarterly

-60K 0 60K 120K 180K Q1 '10: 0 Q2 '10: 0 Q3 '10: 0 Q4 '10: -54K Q1 '11: -5K Q2 '11: -14K Q3 '11: -6K Q4 '11: 3K Q1 '12: 0 Q2 '12: 1K Q3 '12: 88K Q4 '12: 158K Q1 '13: 19K Q2 '13: 44K Q3 '13: 60K Q4 '13: 19K Q1 '14: 0 Q2 '14: 8K Q3 '14: -2K Q4 '14: -2K Q1 '15: 7K Q2 '15: 20K Q3 '15: 0 Q4 '15: 0 Q1 '16: 0 Q2 '16: 0 Q3 '16: 0 Q4 '16: 0 Q1 '17: 0 Q2 '17: 0 Q3 '17: 0 Q4 '17: 0 Q1 '18: 0 Q2 '18: 0 Q1 '19: 0 Q1 '20: 0 Q1 '10 Q2 '11 Q3 '12 Q4 '13 Q1 '15 Q2 '16 Q3 '17 Q1 '20

Operating Income Quarterly

-240M -160M -80M 0 80M 160M 240M Q3 '16: -2.5M Q4 '16: -822K Q1 '17: -1.5M Q2 '17: -1.3M Q3 '17: -126.9M Q4 '17: -5.9M Q1 '18: -7.2M Q2 '18: -5.2M Q3 '18: -234.7M Q4 '18: -3.1M Q1 '19: -4.1M Q2 '19: -2.3M Q3 '19: -8.9M Q4 '19: 31.2M Q1 '20: 1.1M Q2 '20: -1.6M Q3 '20: -1.9M Q4 '20: -2.2M Q1 '21: -29M Q2 '21: -4.4M Q3 '21: -6M Q4 '21: -18.2M Q1 '22: -5.4M Q2 '22: -3M Q3 '22: -7M Q4 '22: -5.8M Q1 '23: -3.7M Q2 '23: -3.6M Q3 '23: -3.1M Q4 '23: -3.2M Q1 '24: -3.1M Q2 '24: -3.9M Q3 '24: -3.6M Q4 '24: -3.8M Q1 '25: -1.9M Q2 '25: -1.5M Q3 '25: -3.4M Q4 '25: -5.6M Q1 '26: -2.8M Q2 '26: -4.5M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-270M -180M -90M 0 90M 180M 270M Q3 '16: -3.6M Q4 '16: -2.8M Q1 '17: -5.1M Q2 '17: -2.5M Q3 '17: -130.6M Q4 '17: -6M Q1 '18: -10.1M Q2 '18: -9.1M Q3 '18: -235.8M Q4 '18: -4.2M Q1 '19: -4.5M Q2 '19: -2.8M Q3 '19: -29.9M Q4 '19: -1.5M Q1 '20: -1.7M Q2 '20: -17.4M Q3 '20: -2.9M Q4 '20: 8.6M Q1 '21: -29.7M Q2 '21: -4.9M Q3 '21: -5.5M Q4 '21: -18M Q1 '22: -5.4M Q2 '22: -3M Q3 '22: -6.9M Q4 '22: -5.6M Q1 '23: -227K Q2 '23: -2M Q3 '23: -2.4M Q4 '23: -3M Q1 '24: -2.3M Q2 '24: -3.7M Q3 '24: -3.4M Q4 '24: -3.8M Q1 '25: -776K Q2 '25: -30.2M Q3 '25: 8.3M Q4 '25: -7.5M Q1 '26: -2.8M Q2 '26: -4.5M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

0 50K 100K 150K Q1 '10: 0 Q2 '10: 0 Q3 '10: 0 Q4 '10: 65K Q1 '11: 25K Q2 '11: 15K Q3 '11: 8K Q4 '11: 0 Q1 '12: 1K Q2 '12: 0 Q3 '12: 32K Q4 '12: 61K Q1 '13: 69K Q2 '13: 12K Q3 '13: 123K Q4 '13: 22K Q1 '14: 0 Q2 '14: 17K Q3 '14: 5K Q4 '14: 35K Q1 '15: 0 Q2 '15: 0 Q3 '15: 0 Q4 '15: 0 Q1 '16: 0 Q2 '16: 0 Q3 '16: 0 Q4 '16: 0 Q1 '17: 0 Q2 '17: 0 Q3 '17: 0 Q4 '17: 0 Q1 '18: 0 Q2 '18: 0 Q1 '19: 0 Q1 '20: 0 Q1 '10 Q2 '11 Q3 '12 Q4 '13 Q1 '15 Q2 '16 Q3 '17 Q1 '20

Operating Cash Flow Quarterly

-6M -4M -2M 0 2M 4M 6M Q3 '16: -563K Q4 '16: -135K Q1 '17: -650K Q2 '17: -391K Q3 '17: -2.2M Q4 '17: -2.2M Q1 '18: -4.2M Q2 '18: -1.8M Q3 '18: -3.4M Q4 '18: -1.2M Q1 '19: -961K Q2 '19: -1.1M Q3 '19: -1.1M Q4 '19: -485K Q1 '20: -223K Q2 '20: -3.4M Q3 '20: -1.7M Q4 '20: -1.9M Q1 '21: -3.7M Q2 '21: -4.3M Q3 '21: -3.9M Q4 '21: -3.7M Q1 '22: -5.2M Q2 '22: -2.8M Q3 '22: -2.9M Q4 '22: -4.3M Q1 '23: -2.9M Q2 '23: -1.9M Q3 '23: -2M Q4 '23: -2M Q1 '24: -4.2M Q2 '24: -3.5M Q3 '24: -2.7M Q4 '24: -2.5M Q1 '25: -2.2M Q2 '25: -3M Q3 '25: -3.7M Q4 '25: -4M Q1 '26: -2.5M Q2 '26: -4.3M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q1 '17: -650K Q2 '17: -391K Q3 '17: -2.2M Q4 '17: -2.2M Q1 '18: -4.2M Q2 '18: -1.8M Q3 '18: -3.4M Q4 '18: -1.3M Q1 '19: -961K Q2 '19: -1.1M Q3 '19: -1.1M Q4 '19: -485K Q2 '17 Q4 '17 Q2 '18 Q4 '18 Q2 '19 Q4 '19

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

-250M 0 250M 500M 750M Q1 '12: 283M Q2 '12: 329.3M Q1 '13: 717.7M Q2 '13: 573.1M Q1 '14: 573.1M Q2 '14: 573.1M Q3 '14: 590.1M Q1 '15: 2.4M Q2 '15: 4.9M Q3 '15: 2.4M Q1 '16: 17.4M Q2 '16: 25.4M Q3 '16: 27.5M Q1 '17: 191.8K Q2 '17: -5.14 Q3 '17: 16M Q1 '18: 50.1M Q2 '18: -0.18 Q3 '18: 50.2M Q1 '19: 51.1M Q1 '20: 70.1M Q1 '21: 16.2M Q2 '21: 33.5M Q3 '21: 31.4M Q1 '22: 32.5M Q2 '22: 31.2M Q3 '22: 31.4M Q1 '23: 1.1M Q2 '23: 1.3M Q3 '23: 1.4M Q1 '24: 1.4M Q2 '24: 1.7M Q3 '24: 2.2M Q1 '25: 2.3M Q2 '25: 2.8M Q3 '25: 3.9M Q1 '26: 30.3M Q2 '26: 38.8M Q1 '13 Q1 '15 Q3 '16 Q2 '18 Q2 '21 Q1 '23 Q3 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-50.00 0.00 50.00 100.00 150.00 Q3 '13: 0.00 Q4 '13: -0.01 Q1 '14: -0.01 Q2 '14: -0.01 Q3 '14: -0.02 Q4 '14: -0.04 Q1 '15: -8.65 Q2 '15: -3.18 Q3 '15: -2.46 Q4 '15: -12.37 Q1 '16: -2.92 Q2 '16: -8.33 Q3 '16: -8.91 Q4 '16: 120.38 Q1 '17: 93.18 Q2 '19: -4.91 Q3 '19: -0.72 Q4 '20: -10.93 Q1 '21: -12.74 Q2 '21: -8.77 Q3 '21: -8.30 Q4 '21: -2.67 Q1 '22: -1.01 Q2 '22: -0.96 Q3 '22: -1.01 Q4 '22: -19.67 Q1 '23: -19.71 Q2 '23: -21.10 Q3 '23: -22.65 Q4 '23: -5.64 Q1 '24: -7.07 Q2 '24: -7.75 Q3 '24: -7.51 Q4 '24: -7.00 Q1 '25: -5.69 Q2 '25: -14.44 Q3 '25: -11.87 Q4 '25: -6.68 Q1 '26: -6.46 Q2 '26: 4.34 Q3 '14 Q4 '15 Q1 '17 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.